Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
Qatar Cardiometabolic Study Using AI
Plain English Summary
Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence is a Not Applicable clinical trial sponsored by Weill Cornell Medical College in Qatar studying Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes, Artifical Intelligence. This study uses AI to track heart health in patients with diabetes or prediabetes who have had a heart attack. It’s for adults in Qatar and the Gulf region with a history of heart issues and diabetes or prediabetes. Participation involves reviewing medical records, and there’s no direct interaction with researchers. Alternatives include regular check-ups with a doctor, but this study provides insights into predicting future heart problems. The trial aims to enroll 10000 participants.
Official Summary
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence.In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of patients presenting with acute coronary syndrome who have type 2 diabetes or prediabetes.This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality.An artificial intelligence component will be used to develop and validate machine-learning-based risk prediction models to forecast adverse cardiovascular outcomes in patients with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during patient care to identify predictors of cardiovascular events.
Who Can Participate
Here is what you need to know about eligibility for this trial. Adults aged 18 and over, Qatari or Arab nationality, admitted for heart attack or heart failure. Must have diabetes (HbA1C ≥ 6.5%) or prediabetes (5.7% ≤ HbA1C ≤ 6.4%). Cannot be non-Qatari or non-Arab, non-diabetic (HbA1C < 5.7%), or have no history of heart issues. This trial is studying Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes, Artifical Intelligence, so participants generally need a confirmed diagnosis.
What They're Measuring
The primary outcome measures will help patients understand their risk of future heart problems and guide preventive care. The specific primary outcome measures are: For ACS patients (5 years); For Heart Failure patients (5 years). These endpoints are how researchers determine whether the treatment is effective and will form the basis of any future regulatory submissions.
About This Phase
This study does not have a traditional clinical phase designation. It may be an observational study that follows patients without intervening in their care, an expanded access or compassionate use program, or other non-interventional research. These studies contribute valuable data about disease progression, treatment patterns, and patient outcomes.
Why This Trial Matters
This study is crucial as it aims to fill the gap in understanding and predicting heart disease in high-risk populations, particularly in Qatar and the Gulf region. This research targets Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes, Artifical Intelligence, where improved treatment options are needed.
Investor Insight
The market size is significant given the high prevalence of diabetes and heart disease in the region, with a competitive landscape focused on AI in healthcare. The large enrollment target of 10000 participants suggests significant investment in this program.
Is This Trial Right for Me?
Ask your doctor if you have a history of heart issues and diabetes or prediabetes. Participation involves reviewing your medical records, with no direct interaction with researchers. The trial is being conducted at 1 site. Always discuss clinical trial participation with your healthcare provider before making any decisions. This information is for educational purposes only and is not medical advice.
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 10,000 participants
Primary Outcomes
- For ACS patients (5 years)
- For Heart Failure patients (5 years)
Secondary Outcomes
- Cardiometabolic Endpoints (5 years)
Full Eligibility Criteria
Inclusion Criteria: \- 1. Age ≥ 18 2. Qatari and Arab patients 3. Patients admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF). 4\. Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or Pre-diabetes: 5.7 ≥ HbA1C ≤ 6.4 Exclusion Criteria: * 1\. Non-Qatari or non-Arab patients 2. Non-diabetic: HbA₁c \< 5.7% 3. This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.
Trial Locations
- Hamad Medical Corporation, Doha, Qatar
Frequently Asked Questions
What is clinical trial NCT07515807?
NCT07515807 is a Not Applicable OBSERVATIONAL study titled "Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence." It is currently not yet recruiting and is sponsored by Weill Cornell Medical College in Qatar. The trial targets enrollment of 10000 participants.
What conditions does NCT07515807 study?
This trial investigates treatments for Cardio Vascular Disease, Acute Coronary Syndromes (ACS), Type 2 Diabetes, Pre Diabetes, Artifical Intelligence. The primary condition under study is Cardio Vascular Disease.
What does Not Applicable mean for NCT07515807?
This study does not have a defined clinical phase. It may be an observational study, expanded access program, or other non-interventional research.
What is the current status of NCT07515807?
This trial is currently "Not Yet Recruiting." It started on 2026-07-16. The estimated completion date is 2030-07-16.
Who is sponsoring NCT07515807?
NCT07515807 is sponsored by Weill Cornell Medical College in Qatar. The sponsor is responsible for funding, designing, and overseeing the clinical trial.
How many people can participate in NCT07515807?
The trial aims to enroll 10000 participants. The trial has not yet started recruiting.
How is NCT07515807 designed?
This is a observational study.
What are the primary outcomes being measured in NCT07515807?
The primary outcome measures are: For ACS patients (5 years); For Heart Failure patients (5 years). These are the main endpoints researchers use to determine whether the treatment is effective.
Where is NCT07515807 being conducted?
This trial is being conducted at 1 site, including Doha (Qatar).
Where can I find official information about NCT07515807?
The official record for NCT07515807 is available on ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT07515807. This government database provides the most up-to-date and detailed information about the trial.
What is NCT07515807 testing in simple terms?
This study uses AI to track heart health in patients with diabetes or prediabetes who have had a heart attack. It’s for adults in Qatar and the Gulf region with a history of heart issues and diabetes or prediabetes.
Why is this trial significant?
This study is crucial as it aims to fill the gap in understanding and predicting heart disease in high-risk populations, particularly in Qatar and the Gulf region.
What are the potential risks of participating in NCT07515807?
There are no direct risks or side effects as it involves reviewing medical records. However, there’s a potential for data privacy concerns. As with any clinical trial, participants are closely monitored and can withdraw at any time.
Should I consider participating in NCT07515807?
Ask your doctor if you have a history of heart issues and diabetes or prediabetes. Participation involves reviewing your medical records, with no direct interaction with researchers. Always discuss clinical trial participation with your healthcare provider to determine if it is appropriate for your specific situation.
What does NCT07515807 signal from an investment perspective?
The market size is significant given the high prevalence of diabetes and heart disease in the region, with a competitive landscape focused on AI in healthcare. This is a Not Applicable trial, which is in early development stages.
What happens if the treatment in this trial doesn't work?
Participation involves reviewing medical records, and there’s no direct interaction with researchers. Participants in clinical trials always have the right to withdraw and pursue alternative treatments. The study team will help transition patients to other available options.
Related Conditions
More Cardio Vascular Disease Trials
This analysis is AI-generated and does not constitute medical advice. Always consult your healthcare provider before making decisions about clinical trial participation.